bluebird bio, Inc. (BLUE) Financials
BLUE Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 613.6 million | 391.1 million |
2023-06-30 | 663.4 million | 374.4 million |
2023-03-31 | 692.7 million | 338.0 million |
2022-12-31 | 554.9 million | 358.6 million |
BLUE Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -63.9 million | 4.9 million |
2023-06-30 | -73.4 million | 5.8 million |
2023-03-31 | -87.7 million | 5.4 million |
2022-12-31 | -61.4 million | 4.7 million |
BLUE Net Income
No data available :(
BLUE Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 174.3 million | - | 303.7 million |
2023-06-30 | 245.3 million | - | 306.9 million |
2023-03-31 | 318.3 million | - | 273.4 million |
2022-12-31 | 181.7 million | - | 281.4 million |
BLUE Shares Outstanding
BLUE Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 2.0 million | 45.5 million | 40.7 million | - |
2023-06-30 | 705000 | 42.3 million | 40.3 million | - |
2023-03-31 | 1.1 million | 46.1 million | 37.4 million | - |
2022-12-31 | 5.1 million | 45.9 million | 30.7 million | - |
BLUE Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 12.4 million | 11.0 million |
2023-06-30 | 6.9 million | 9.6 million |
2023-03-31 | 2.4 million | 3.4 million |
2022-12-31 | 62000 | 22000 |
BLUE
Price: $0.92
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.63 USD
P/E Ratio: -1.52
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 3.0 million
Ebitda: -74.0 millionMarket Capitalization: 227.4 million